FOOD AND DRUG ADMINISTRATION

Center for Drug Evaluation and Research (CDER)

Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee(PCNS) and the Psychopharmacologic Drugs Advisory Committee (PDAC)

AGENDA July 10, 2008

The committee will discuss the results of FDA's meta-analysis and issues related to antiepileptic drugs and suicidality.

8:00 a.m.	Call to Order Introduction of Committee	Larry Goldstein, M.D. Chair, PCNS
	Conflict of Interest Statement	Yvette Waples, PharmD Designated Federal Official
8:15 a.m.	Opening Remarks	Russell Katz, M.D., Director Division of Neurology Products, CDER, FDA
8:30 a.m.	Antiepileptic Drugs and Suicidality: Background	Evelyn Mentari, M.D., M.S., Clinical Safety Reviewer Division of Neurology Products, CDER, FDA
	Antiepileptic Drugs and Suicidality: Statistical Evaluation	Mark Levenson, Ph.D., Statistical Safety Reviewer Quantitative Safety & Pharmacoepidemiology Group, Division of Biometrics 6, CDER, FDA
	Antiepileptic Drugs and Suicidality: Discussion	Evelyn Mentari, M.D., M.S., Clinical Safety Reviewer Division of Neurology Products, CDER, FDA
9:30 a.m.	Questions from the Committee	
10:00 a.m.	Break	
10:15 a.m.	Neurontin/Lyrica: Potentially Suicide Related Adverse Events	Christopher Wohlberg, M.D., Ph.D. Global Medical Team Leader, Lyrica Global Medical Therapeutic Area Lead, Pain Pfizer, Inc.
10:35 a.m.	Lamictal® (lamotrigine): Analysis of Suicidality Data	Jack Modell, M.D. Vice President Clinical Development for Neurosciences GlaxoSmithKline
10:50 a.m.	Preliminary Statistical Comments on Pfizer Gabapentin and Pregabalin Analysis	Mark Levenson, Ph.D., Statistical Safety Reviewer Quantitative Safety & Pharmacoepidemiology Group, Division of Biometrics 6, CDER, FDA
11:05 a.m.	Questions from the Committee	
11:45 a.m.	Lunch	
1:00 p.m.	Open Public Hearing	
3:00 p.m.	Break	
3:15 p.m.	Discussion and questions to the Committee	
5:00 p.m.	Adjourn	